AFAP1-AS1 is a long non-coding RNA that is associated with tumorigenesis and poor prognosis in a variety of cancers. We have been suggested that AFAP1-AS1 increases tumorigenesis in laryngeal carcinoma specifically by enhancing stemness and chemoresistance. We assessed AFAP1-AS1 expression in human laryngeal specimens, paired adjacent normal tissues and human HEp-2 cells. Indeed, we found not only that AFAP1-AS1 was up-regulated in laryngeal carcinoma specimens and cells, but also that stemness-associated genes were overexpressed. Silencing of AFAP1-AS1 promoted HEp-2 cell chemoresistance under cisplatin treatment. Expression of AFAP1-AS1 was increased in drug-resistant Hep-2 cells. We then probed the mechanism of AFAP1-AS1 activity and determined that miR-320a was a potential molecular target of AFAP1-AS1. Luciferase reporter and qRT-PCR assays of AFAP1-AS1 and miR-320a levels in human specimens and cell cultures indicated that AFAP1-AS1 negatively regulates miR-320a. To discover the molecular mechanism of miR320a, we again used the DIANA Tools algorithm to predict its genetic target, RBPJ.
| INTRODUCTION
Laryngeal carcinoma is the most prevalent of head and neck cancers, accounting for about 25% to 30% of cases. 1, 2 While there have been significant advances made in patient outcomes, these are largely due to improvements in prevention, such as reductions in cigarette smoking, and early diagnosis. Early stage laryngeal carcinomas (T1 and T2) can have up to an 80% to 90% cure rate, whereas advanced tumours (T3 or T4, N1-N3 or M1) have only a 60% chance of cure. 3, 4 It is therefore crucial to improve not just the methods of diagnosing laryngeal carcinoma, but also to advance treatment strategies for later stage disease. In the past few decades, the primary treatment approach evolved from total laryngectomy towards non-surgical, organ-preserving interventions with radiotherapy or chemoradiotherapy. 5 Cisplatin is currently the chemotherapeutic standard and can be used in combination with taxane and 5-fluorouracil, and when followed by radiotherapy can serve as an alternative to extensive surgery. 6 However, treatment successes are severely limited by chemoresistance and cancer cell stemness, which both enhances chemoresistance and contributes to cancer cell proliferation in its own right. 7, 8 In this study, we have identified the AFAP1-AS1/miR-320a/RBPJ axis as a regulator of laryngeal carcinoma cell stemness and chemoresistance.
It is well established that the prevalence of cancer stem cells (CSCs) and heightened propensity for tumours to maintain CSC subpopulations, also known as stemness, cause increased cancer aggressiveness and poorer patient outcomes. 9, 10 In fact, it was recently discovered that reducing CD133+ CSC populations in laryngeal carcinoma cell cultures can heighten the effectiveness of cisplatin treatment. 11 These results were due not only to the impact of reducing CSCs on cancer cell longevity, but also to the substantial effects that
CSCs have on enhancing chemoresistance. 12, 13 It is likely that inherent cancer cell drug resistance arises from the natural tendency of CSCs for heightened DNA repair, cell quiescence and the expression of ATP-binding cassette transporters that promote drug efflux. 14, 15 When CSCs survive an initial course of chemotherapy, they can adopt a drug resistance phenotype that contributes to acquired chemoresistance. 16 In laryngeal carcinoma, a number of mechanisms of chemoresistance have been identified, 17, 18 including the dysregulation of microRNAs (miRNAs) that regulate gene expression. 19 In this study, we sought to identify a novel molecular mechanism of laryngeal carcinoma stemness and chemoresistance.
Actin filament-associated protein 1 antisense RNA1 (AFAP1-AS1) is a long non-coding RNA (lncRNA) derived from the antisense strand of DNA at the AFAP1 coding gene locus. It has been associated with several cancer types, especially head and neck squamous cell carcinomas (HNSCCs). lncRNAs are RNA transcripts longer than 200 nucleotides but that lack significant open-reading frames. 20 While not ultimately translated into proteins, lncRNAs participate in numerous physiological activities, including chromosome modification, transcriptional activation and interference, and cell growth, differentiation and apoptosis. 21, 22 Apart from their role in cellular physiology, lncRNAs, especially when dysregulated, can contribute to oncogenesis. 23, 24 In 2013, Wu et al 25 determined that AFAP1-AS1 overexpression promotes oncogenesis in Barrett's esophagus (BE) and oesophageal adenocarcinoma. AFAP1-AS1 has also been implicated in a number of other cancers, including hepatocellular carcinoma, 26 lung cancer 27 and nasopharyngeal carcinoma. 28 In this study, we have been suggested that AFAP1-AS1 promotes oncogenesis in laryngeal carcinoma by enhancing cancer cell stemness and chemoresistance. Ultimately, we found not only that AFAP1-AS1 increases laryngeal carcinoma stemness and chemoresistance, but also that it does so by regulating miR-320a activity and RBPJ expression. This study therefore provides the basis for developing biomarkers and treatment strategies with the potential to dramatically improve patient outcomes. 
| MATERIALS AND METHODS

| Patient specimens
| Tumour sphere formation
| 4255
The medium was changed 6 hour post-transfection, and luciferase activity was measured after 48 hour using the dual-luciferase reporter assay system (Promega, Madison, WI, USA).
| Western blot
HEp-2 cells were harvested in RIPA buffer with protease inhibitor (Beyotime, Beijing, China). Lysates were centrifuged, and protein was quantified using the BCA assay kit (Beyotime). Lysates were resolved by electrophoresis, transferred to a poly-vinylidene difluoride membrane (Millipore, Bedford, MA, USA) and probed with primary antibodies against RBPJ or GAPDH (Abcam, Cambridge, Massachusetts, USA) overnight at 4°C. The antibodies were diluted 1:1000. After secondary antibody horseradish peroxidase (HRP) conjugation, the enhanced chemiluminescence detection kit (Beyotime) was used for signal detection.
| Cell viability
HEp-2 cells were seeded in a 96-well plate at a density of 3000 cells per well. Cells were incubated with 10% CCK8 reagent (DoJinDo Laboratories, Japan) for 1 hour at 37°C. Plates were then analysed using an automatic spectrometer (Multimode Reader; EnSpire) at 450 nm.
| Cell DAPI staining
We conducted nuclear DAPI staining to access cell apoptosis using Cell Apoptosis DAPI Detection Kit (GenScript, Piscataway, NJ) according to manufacturer's instructions.
| Statistical analysis
All of the results are expressed as the means and totals derived from independent experiments. When comparing two groups, Student's unpaired t test (two-tailed) was used. For all tests, a P value <.05 was considered significant. The Benjamini and Hochberg false discovery rate was used as a correction for multiple testing. Error bars represent the SDs of at least three independent experiments.
3 | RESULTS
| The expression of AFAP1-AS1 is up-regulated in laryngeal carcinoma specimens and promotes laryngeal carcinoma cell stemness
To determine whether AFAP1-AS1 contributes to the tumorigenesis of laryngeal carcinoma, we used qRT-PCR to assess AFAP1-AS1 Figure 1C ). These genes were used as markers to indicate the stemness of CSC. [29] [30] [31] To further explore AFAP1-AS1 function in laryngeal carcinoma cell development, we knocked down AFAP1-AS1 expression using siRNA transfection and confirmed silencing with qRT-PCR ( Figure 1D ). We then used qRT-PCR to demonstrate that stemness-associated gene expression in the AFAP1-AS1-silenced cells was significantly reduced compared with control cells ( Figure 1E ). Using tumour sphere assays, we then demonstrated that AFAP1-AS1 moderately inhibited cell self-renewal ( Figure 1F ). Overall, these results suggest that AFAP1-AS1 contributes to laryngeal carcinoma tumorigenesis by promoting cancer cell stemness.
| AFAP1-AS1 enhances cisplatin resistance in laryngeal carcinoma cells
Chemoresistance is an essential characteristic of CSC. 32 To investigate whether AFAP1-AS1 functions as a dominant determinant of chemoresistance in laryngeal carcinoma cells, we treated AFAP1-AS1-silenced HEp-2 cells with 4 lmol L À1 cisplatin and analysed AFAP1-AS1 expression at different time-points. AFAP1-AS1 expression was increased in a time-dependent manner and reached peak expression 24 hour after treatment (Figure 2A ).
AFAP1-AS1-silenced HEp-2 cells were then treated with various concentration of cisplatin. CCK8 assays of these cells demonstrated significant inhibition of HEp-2 cell viability ( Figure 2B ).
Apoptosis assays of AFAP1-AS1-silenced HEp-2 cells treated with 8 lmol L À1 cisplatin showed that silencing AFAP1-AS1 significantly elevated cell apoptosis ( Figure 2C ). The nucleus in apoptotic cells showed sign of blebbing or fragmentation. We then generated cisplatin-resistant HEp-2 (HEp-2/R) cells and confirmed their resistance using cell viability assays ( Figure 2D ). Elevated expression of AFAP1-AS1 was found in HEp-2/R cells in contrast to HEp-2 cells ( Figure 2E ).
| AFAP1-AS1 targets miR-320a
To discover the molecular mechanism of AFAP1-AS1, we used the DIANA Tools (www.microrna.gr) miRNA target prediction algorithm. 33 ,34 miR-320a was predicted to bind with AFAP1-AS1 at multiple sites ( Figure 3A ). To verify whether miR-320a is a genetic target of AFAP1-AS1, we cloned the full length AFAP1-AS1 into a luciferase reporter. Luciferase activity decreased by 64% when miR320a was overexpressed as compared with control miRNA (miRControl) ( Figure 3B ). Furthermore, we found that AFAP1-AS1 F I G U R E 3 AFAP1-AS1 targets miR-320a. A, Sequence of the miR-320a binding sites within the human AFAP1-AS1 labelled in blue. B, Luciferase assay in HEp-2 cells, which were cotransfected with miR-Control or miR-320a and a luciferase reporter containing the full length AFAP1-AS1. **P < .01, compared with control miRNA transfected cells. C, Expression of miR-320a in AFAP1-AS1 silenced HEp-2 cells. **P < .01, compared with control siRNA transfected cells by qRT-PCR. D, Expression of AFAP1-AS1 in miR-320a overexpression HEp-2 cells by qRT-PCR. E, Spearman's correlation analysis was used to determine the correlation between AFAP1-AS1 and miR-320a expression in human laryngeal carcinoma specimens. r = À5.9
down-regulation in HEp-2 cells caused the endogenous level of miR-320a to increase significantly ( Figure 3C ). However, overexpression of miR-320a did not alter AFAP1-AS1 levels ( Figure 3D ).
We then performed qRT-PCR to analyse the correlation between AFAP1-AS1 and miR-320a levels in 24 laryngeal carcinoma specimens. The endogenous expression of AFAP1-AS1 was negatively associated with the expression of the miR-320a ( Figure 3E ). The totality of these findings suggests that AFAP1-AS1 negatively regulates miR-320a activity.
| miR-320a reduces stemness and cisplatin resistance in laryngeal carcinoma cells
To explore the possible role of miR-320a in laryngeal carcinoma cell stemness, we performed qRT-PCR to detect miR-320a expression between parental cells and stemness-enriched cell spheres. We found that miR-320a was down-regulated in cell spheres ( Figure 4A ).
To further explore miR-320a function in laryngeal carcinoma cell development, we increased miR-320a expression by miR-320a transfection, confirming miR-320a overexpression by qRT-PCR (Figure 4B) . qRT-PCR of these cells then revealed that expression levels of stemness-associated genes were significantly reduced in miR320a overexpression cells as compared to miR-control cells (Figure 4C) . Tumour sphere assays then showed that AFAP1-AS1 overexpression moderately inhibited cell self-renewal ( Figure 4D ). To investigate whether miR-320a regulates laryngeal carcinoma cell cisplatin resistance, miR-320a overexpression HEp-2 cells were treated with various concentration of cisplatin. CCK8 assays demonstrated that miR-320a overexpression significantly inhibited HEp-2 cell viability ( Figure 4E ). Apoptosis assays then revealed that miR-320a overexpression in cisplatin-treated HEp-2 cells significantly elevated apoptosis ( Figure 4F ). Furthermore, decreased expression of AFAP1-A miR-320a was found in HEp-2/R cells in contrast to HEp-2 cells ( Figure 4G ). These results indicate that miR-320a overexpression reduces laryngeal carcinoma cell stemness while increasing chemosensitivity to cisplatin.
| miR-320a targets RBPJ
To discover the molecular mechanism of miR-320a, we used the DIANA Tools algorithm to predict its target gene, RBPJ (Figure 5A ). To verify whether RBPJ was a target gene of miR-320a, we cloned the 3 0 -untranslated regions (UTR) of RBPJ into a luciferase reporter. The luciferase activity of the RBPJ 3 0 -UTR decreased by 60% when miR-320a was overexpressed as compared with control ( Figure 5B ). Furthermore, we found that miR-320a overexpression in HEp-2 cells reduced both mRNA and protein levels of RBPJ ( Figure 5C,D) . qRT-PCR of 24 human laryngeal carcinoma specimens revealed that endogenous expression of miR-320a was negatively associated with the expression of the RBPJ ( Figure 5E ). Overall, these experiments highly suggest that miR-320a negatively regulates RBPJ expression.
| AFAP1-AS1 regulates laryngeal carcinoma cells through miR-320a/RBPJ
To investigate whether AFAP1-AS1 regulates RBPJ expression, we analysed mRNA and protein levels of RBPJ in AFAP1-AS1 silenced
HEp-2 cells. Indeed, when AFAP1-AS1 was silenced, RBPJ expression was significantly inhibited (Figure 6A,B) . As expected, inhibition of miR-320a increased RBPJ mRNA and protein levels. In addition, miR320a inhibition prevented AFAP1-AS1 silencing that had previously caused RBPJ down-regulation ( Figure 6A,B) . Furthermore, we investigated the role of RBPJ in laryngeal carcinoma cell development. We found down-regulation of RBPJ significantly reduced HEp-2 cell stemness and chemoresistance (Supporting information Figure S1 ).
To analyse whether AFAP1-AS1 regulates laryngeal carcinoma cells finding that miR-320a down-regulation was highly associated with chemoresistance. While there is an impressive amount of research into the role of miR-320a in various cancers and its activity through a wide range of molecular mechanisms, such as the Wnt/beta-catenin 43 and vascular endothelial growth factor pathways, 44 the present study is the first to establish its activity as a negative regulator of laryngeal carcinoma stemness and chemoresistance. It is also the first to demonstrate its regulation of RBPJ expression.
RBPJ plays a crucial role in the notch signalling pathway, including as a primary transcriptional effector and potentially as a maintainer of gene expression programs. 45, 46 When associated with Notch proteins, RBPJ acts as a transcriptional activator, but when not associated with Notch proteins, it exists in complexes with corepressors and serves to block transcription. 47 Even though there are no studies that link RBPJ activity to laryngeal carcinoma, in 2016, Liu et al 48 found that somatic mutations in NOTCH1 correlated strongly with higher rates of recurrence and lower survival in HNSCC. It is likely that genes that regulate Notch signalling, such as RBPJ, are in some way responsible for altering HNSCC prognosis. In this study, we have determined for the first time that RBPJ is crucial for the regulation of laryngeal carcinoma cell stemness and chemoresistance. However, it is important that future studies strive to elucidate its exact mechanism of action. Overall, this study has laid an impressive groundwork for the discovery of clinically relevant biomarkers, treatment targets and strategies to improve chemotherapeutic effectiveness in laryngeal carcinoma.
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